Quantum BioPharma wins FDA IND clearance for Lucid-MS Phase 2 trial in progressive MS

Reuters2026/08/10 11:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Quantum BioPharma secured FDA clearance for its IND, enabling a Phase 2 trial of Lucid-MS in progressive multiple sclerosis.
The study is planned as a randomized, double-blind, placebo-controlled trial, with site selection underway and enrollment expected to start soon.
Quantum BioPharma reported over USD 10 million in cash, digital assets, and liquid investments as of March 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum Biopharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100700PRIMZONEFULLFEED9806576) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Quantum BioPharma wins FDA IND clearance for Lucid-MS Phase 2 trial in progressive MS

You may also like

Crypto prices